Menu
Recruiting NCT04448522

Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma

Phase III Interventional Nasopharyngeal Carcinoma Radiotherapy Chemotherapy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: reduced dosage IMRT, conventional dosage IMRT.
Who it may be relevant to
Registry conditions: Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China, Singapore
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Multicenter Randomized Controlled Trial Comparing Reduced Dose With Regular Dose Intensity-modulated Radiotherapy for Chemotherapy Sensitive Stage II-III Nasopharyngeal Carcinoma

Overview

Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that radiotherapy with reduced dose could significantly reduce the incidence of radiotherapy toxicities, improve the quality of life of patients while ensuring the tumor control rates for NPC patients staged as II-III who are sensitive to induction chemotherapy (imaging evaluation of CR/PR and EBV DNA copy number decreased to 0 copies/mL after induction chemotherapy)

Detailed description

Through multicenter, open-label, randomised clinical trials, patients with NPC staged as II-III with CR/PR according to RECIST criteria and EBV DNA decreased to 0 copies/mL after 3 cycles of GP induction chemotherapy will be randomized into experimental group to receive IMRT of reduced dose (prescribed dose, 63.6 Gy, 2.12 Gy per fractions, 30 fractions) and control group to receive IMRT of conventional dose (prescribed dose, 69.96 Gy, 2.13 Gy per time, 33 fractions). Two cycles of cisplatin chemotherapy will be performed during IMRT. The efficacy, toxicity, and quality of life of patients between the two groups will be compared.

Interventions

  • Radiation reduced dosage IMRT
    1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks. 2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 week
  • Radiation conventional dosage IMRT
    1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks. 2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 week

Primary outcome measures

  • Progress-free survival (PFS) [Time frame: 3 years]
Secondary outcome measures (7)
  • Overall Survival (OS) [Time frame: 3 years]
  • Distant Metastasis-Free Survival (DMFS) [Time frame: 3 years]
  • Locoregional Relapse-Free Survival (LRRFS) [Time frame: 3 years]
  • Incidence of treatment related acute complications [Time frame: up to 1 years]
  • Incidence of treatment related late complications [Time frame: up to 3 years]
  • Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) [Time frame: up to 3 years]
  • Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&N35) [Time frame: up to 3 years]

Eligibility criteria

Inclusion criteria

  • Histologically confirmed non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., WHO type II or type III).
  • Staged as T1-3N1-2M0, T2-3N0M0 (stage II-III) at diagnosis (according to the 8th AJCC edition).
  • Aged between 18-70 years.
  • Karnofsky scale (KPS)≥70.
  • Normal bone marrow function.
  • Evaluated as PR or CR after 3 cycles of GP induction chemotherapy.
  • EBV DNA copy number decreased to 0 copies/mL after 3 cycles of GP induction chemotherapy.
  • Normal liver and kidney function:
  • total bilirubin, AST and ALT levels of no more than 2.5 times the upper normal limit;
  • creatinine clearance rate of at least 60 mL/min or creatinine of no more than 1.5 times the upper normal limit.
  • Given written informed consent.

Exclusion criteria

  • Histologically confirmed keratinized squamous cell carcinoma (WHO type I) or basal squamous cell carcinoma.
  • Recurrent or metastatic nasopharyngeal carcinoma.
  • Evaluated as SD or PD after 3 cycles of GP induction chemotherapy.
  • EBV DNA copy number of more than 0 copies/mL after 3 cycles of GP induction chemotherapy.
  • Pregnancy or lactation (Pregnancy tests should be considered for women in childbearing age, and effective contraception should be emphasized during treatment.)
  • Other invasive malignant diseases in the past, other than cured basal cell skin carcinoma, squamous cell carcinoma, cervical carcinoma in situ.
  • Primary and regional lesions have been treated with chemotherapy or surgery (except diagnostic purpose)
  • Any severe disease, which may cause unacceptable risk factors or affect compliance with the trial, for example, unstable heart disease requiring treatment, kidney disease, chronic hepatitis, poorly controlled diabetes (fasting blood glucose > 1.5×ULN), and mental illness.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

China · 5 centers
  • Sun Yat-sen University Cancer Center — Guangzhou
  • Cancer Center of Guangzhou Medical University — Guangzhou
  • Yuebei People's Hospital — Shaoguan
  • Zhongshan People's Hospital — Zhongshan
  • Wuzhou Red Cross Hospital — Wuzhou
Singapore · 1 center
  • National Cancer Centre Singapore — Singapore

Identifiers

NCT: NCT04448522 · SYSUCC-MYC-2020-1201

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗